Core Viewpoint - The company, Jinkai Biotechnology (301509), emphasizes its commitment to the development of its main business and focuses on technological innovation as the core driving force in the small molecule CDMO sector [1] Group 1: Business Strategy - The company is continuously optimizing resource allocation to enhance its core competitiveness in the small molecule CDMO field [1] - The company will carefully evaluate and advance initiatives that are beneficial for enhancing its long-term value, in alignment with its development strategy, industry trends, and actual operating conditions [1] Group 2: Information Disclosure - The company commits to timely information disclosure if any relevant matters arise that meet the disclosure standards, and stakeholders are advised to refer to announcements published in designated information disclosure media [1]
金凯生科：公司始终专注于主营业务发展